First tranche delivered, larger tranches en route: the same engine that just produced has visibly more already scheduled
The model's full reasoning — Q3 2023 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management describes one identifiable engine of new business with first tranche landed and larger tranches in motion. Need be strict. Transcript: Quanterix Q3 2023. Management discusses transformation, gross margins, cash. New agreement with J&J launched Lucent AD P-tau217 test. Also Lilly collaboration. Need see if there is an engine with first tranche landed and larger tranches already in motion. The question asks: "On this call, does management describe ONE identifiable engine of new business — such as a specific contract, program, product, facility, customer relationship, market, or expansion — for which BOTH of following true: (1) A FIRST TRANCHE HAS ACTUALLY LANDED: a real, concrete portion of that engine's business was actually delivered, shipped, completed, opened, billed, or recognized in the just-reported period — described as accomplished fact with operating substance behind it, not as plan, pipeline, letter of intent, or hoped-for demand; AND (2) LARGER TRANCHES ARE ALREADY IN MOTION BEHIND IT: management identifies further portions of that SAME engine that are already committed, scheduled, contracted, in production, ramping, or otherwise concretely underway — and conveys, directly or plainly in substance, that what has been delivered so far is the SMALLER share, with majority of engine's contribution still ahead over roughly coming year?" Need identify engine. Could be "new scalable production platform" with assays rolling off in January? But that's future. Or "Lucent AD P-tau217 test" launched with J&J. Did they have first tranche landed? They launched test, but did they recognize revenue? They say "launched the Lucent AD P-tau217 blood based biomarker test" - that's a product launch, not necessarily revenue. They mention "Our P-tau217 test achieved sensitivity..." Not mention sales. They have agreement with J&J. But no mention of first tranche delivered. They talk about "we signed a new agreement with Johnson & Johnson Innovative Medicines and launched the Lucent AD P-tau217 blood based biomarker test" - that's a launch, but no revenue recognized. They also mention "we are working with VUMC and ABBS on a clinical trial" - that's ongoing. They mention "we will be focused on upgrades and readiness of our production lines as we introduce new assays in 2024" - future.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| ATAT | Atour Lifestyle Holdings Limited | Q1 2024 | 2024-05-23 | B+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| ZLAB | Zai Lab Limited | Q4 2023 | 2024-02-28 | C |
| VMI | Valmont Industries, Inc. | Q4 2023 | 2024-02-22 | C |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| CLNE | Clean Energy Fuels Corp. | Q2 2023 | 2023-08-09 | C+ |
| LUCD | Lucid Diagnostics Inc. | Q1 2023 | 2023-05-16 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| ARE | Alexandria Real Estate Equities, Inc. | Q4 2022 | 2023-01-31 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CDMO | Avid Bioservices, Inc. | Q3 2022 | 2022-03-08 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| DOV | Dover Corporation | Q2 2021 | 2021-07-20 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| FEIM | Frequency Electronics, Inc. | Q1 2019 | 2018-09-13 | B+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| MGA | Magna International Inc. | Q1 2018 | 2018-05-10 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| HR | Healthcare Realty Trust Incorporated | Q1 2017 | 2017-05-08 | A |
| BDN | Brandywine Realty Trust | Q1 2017 | 2017-04-21 | C+ |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| MTRX | Matrix Service Company | Q3 2016 | 2016-05-05 | D |
| CLF | Cleveland-Cliffs Inc. | Q1 2016 | 2016-04-29 | F |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
CDMO · Q3 2022 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: NO The transcript describes the first phase of the Myford expansion as now operational and scheduling client projects, with management noting they are already utilizing the new space and that an extra $5 million is arguably in backlog attributable to it.
LINC · Q1 2024 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: YES The transcript identifies the new-campus expansion strategy as the engine. East Point opened in Q1 with 29 starts and $90k revenue (first tranche, concrete and delivered).
LTRX · Q3 2024 → YESThe question is about whether management describes one identifiable engine of new business that meets two criteria: a first tranche has actually landed in the just-reported period, and larger tranches...